Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Copyright policy )Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
A 59-year-old man is diagnosed with multiple myeloma. It is recommended that he receive induction therapy followed by high-dose melphalan with autologous hematopoietic stem-cell transplantation. Such transplantation improves the remission rate in myeloma by allowing for the administration of a chemotherapy dose that would otherwise be lethal. This approach is considered appropriate only for relatively young patients without major coexisting illnesses.
- Hôtel-Dieu de Paris France
Male, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Middle Aged, Transplantation, Autologous, Drug Resistance, Neoplasm, Practice Guidelines as Topic, Humans, Multiple Myeloma, Melphalan
Male, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Middle Aged, Transplantation, Autologous, Drug Resistance, Neoplasm, Practice Guidelines as Topic, Humans, Multiple Myeloma, Melphalan
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).171 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!